Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cerus Corp (CERS)

Cerus Corp (CERS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cerus Corp 1220 CONCORD AVENUE SUITE 600 CONCORD CA 94520 USA

www.cerus.com Employees: 275 P: 925-288-6000

Sector:

Medical

Description:

Cerus Corporation is developing medical products based on a platformtechnology that prevents nucleic acid replication. The company's initialapplication of this technology is the development of systems to inactivateviruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation.

Key Statistics

Overview:

Market Capitalization, $K 359,362
Enterprise Value, $K 423,292
Shares Outstanding, K 192,172
Float, K 181,410
% Float 94.40%
Short Interest, K 10,511
Short Float 5.47%
Days to Cover 3.61
Short Volume Ratio 0.72
% of Insider Shareholders 5.60%
% of Institutional Shareholders 78.37%

Financials:

Annual Sales, $ 233,800 K
Annual Net Income, $ -15,630 K
Last Quarter Sales, $ 64,580 K
Last Quarter Net Income, $ -2,180 K
EBIT, $ -8,670 K
EBITDA, $ -7,240 K

Growth:

1-Year Return 32.86%
3-Year Return -34.84%
5-Year Return -69.49%
5-Year Revenue Growth 104.64%
5-Year Earnings Growth 78.38%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.01 on 03/02/26
Next Earnings Date 05/07/26
Earnings Per Share ttm -0.08
EPS Growth vs. Prev Year 0.00%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

CERS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -26.09%
Return-on-Assets % -7.29%
Profit Margin % -6.69%
Debt/Equity 1.29
Price/Sales 1.70
Price/Cash Flow N/A
Price/Book 5.38
Book Value/Share 0.34
Interest Coverage -0.83
60-Month Beta 1.63
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.